uniQure (NASDAQ:QURE) Trading Up 6.6% – Here’s Why

uniQure N.V. (NASDAQ:QURE)’s stock price rose 6.6% during mid-day trading on Tuesday . The company traded as high as $21.93 and last traded at $21.8430. Approximately 802,392 shares changed hands during mid-day trading, a decline of 58% from the average daily volume of 1,911,649 shares. The stock had previously closed at $20.50.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Neutral Sentiment: Coverage notes uniQure’s Fabry trial is making progress but also highlights an ongoing safety review and attendant regulatory/legal risks that could complicate timelines and approvals. UniQure Balances Fabry Trial Progress With Safety Review And Legal Risks
• Negative Sentiment: Multiple law firms have filed or announced securities class actions alleging uniQure misled investors about disclosures during the Sept. 24–Oct. 31, 2025 period; these actions increase potential litigation exposure and management distraction. Kessler Topaz Class Action Announcement
• Negative Sentiment: Pomerantz LLP issued an investor alert reminding shareholders of a class action and upcoming deadlines, signaling more solicitation activity and potential consolidation of plaintiffs. Pomerantz Investor Alert
• Negative Sentiment: Rosen Law Firm and other plaintiff firms (Bernstein Liebhard, Holzer & Holzer, Robbins LLP, Robbins, etc.) are actively soliciting clients and encouraging motions to be lead plaintiff by the April 13, 2026 deadline—this increases the likelihood of coordinated litigation. Rosen Law Firm Announcement
• Negative Sentiment: One complaint (Scocco v. uniQure N.V., et al.) has been filed in the Southern District of New York, formalizing the litigation and naming uniQure as defendant; a filed federal suit can lengthen resolution and raise potential settlement or judgment risk. Globe and Mail / TheNewswire: Class Action Announcement

Analyst Ratings Changes

A number of research firms recently weighed in on QURE. Stifel Nicolaus lowered their price objective on shares of uniQure from $50.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, December 11th. Barclays assumed coverage on shares of uniQure in a research note on Tuesday, January 27th. They issued an “equal weight” rating and a $31.00 target price for the company. Benchmark reiterated a “buy” rating on shares of uniQure in a research note on Tuesday, November 4th. William Blair reissued a “market perform” rating on shares of uniQure in a report on Tuesday, November 11th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price objective on shares of uniQure in a report on Tuesday, February 10th. Ten analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $58.33.

uniQure Stock Performance

The stock’s 50 day moving average price is $23.34 and its two-hundred day moving average price is $29.28. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $1.35 billion, a price-to-earnings ratio of -4.95 and a beta of 0.66.

Insider Activity

In other uniQure news, Director Jack Kaye sold 6,390 shares of the stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $27.28, for a total value of $174,319.20. Following the completion of the transaction, the director directly owned 20,439 shares of the company’s stock, valued at approximately $557,575.92. This trade represents a 23.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Robert Gut sold 25,613 shares of uniQure stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $24.62, for a total transaction of $630,592.06. Following the sale, the director owned 32,342 shares of the company’s stock, valued at approximately $796,260.04. The trade was a 44.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 4.79% of the company’s stock.

Institutional Trading of uniQure

A number of institutional investors have recently bought and sold shares of the company. Private Trust Co. NA purchased a new position in shares of uniQure in the third quarter valued at $28,000. Jones Financial Companies Lllp grew its stake in uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 509 shares during the last quarter. CIBC Private Wealth Group LLC acquired a new stake in uniQure in the 3rd quarter valued at about $50,000. Torren Management LLC acquired a new position in uniQure during the fourth quarter worth about $28,000. Finally, FNY Investment Advisers LLC raised its position in uniQure by 76.7% during the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 718 shares during the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.